HAVN Life Sciences Inc.
HAVLF · OTC
1/31/2023 | 10/31/2022 | 7/31/2022 | 4/30/2022 | |
|---|---|---|---|---|
| Revenue | -$0 | $0 | $0 | $0 |
| % Growth | -103.8% | 363.5% | -68.6% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | 690.9% | 64.1% | 32.4% | 31.5% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $1 | $1 | $1 | $2 |
| SG&A Expenses | $1 | $1 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | -$0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1 | $1 | $1 | $2 |
| Operating Income | -$1 | -$1 | -$1 | $1 |
| % Margin | 6,222.1% | -397.6% | -1,401.4% | 552.4% |
| Other Income/Exp. Net | $0 | -$1 | -$3 | -$13 |
| Pre-Tax Income | -$1 | -$2 | -$4 | -$11 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | -$2 | -$4 | -$11 |
| % Margin | 5,734.1% | -787.5% | -5,747.4% | -5,253.1% |
| EPS | -0.071 | -0.41 | -27.05 | -2.38 |
| % Growth | 82.6% | 98.5% | -1,036.6% | – |
| EPS Diluted | -0.071 | -0.41 | -27.05 | -2.38 |
| Weighted Avg Shares Out | 10 | 6 | 0 | 5 |
| Weighted Avg Shares Out Dil | 10 | 6 | 0 | 5 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$1 | -$1 | -$11 |
| % Margin | 5,733.3% | -191.7% | -1,334.3% | -5,169.6% |